Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	2.32B +15.7%
Revenue (ttm)	959.90M +24.3%
Net Income	181.27M +0.2%
EPS	3.09 -0.1%
Shares Out	58.24M
PE Ratio	12.87
Forward PE	10.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	705,474
Open	39.16
Previous Close	39.52
Day's Range	39.03 - 39.83
52-Week Range	25.52 - 40.87
Beta	0.91
Analysts	Buy
Price Target	46.10 (+15.92%)
Earnings Date	Aug 4, 2026

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 293
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.

Analyst Summary

According to 10 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $46.1, which is an increase of 15.92% from the latest price.

Price Target

$46.1

(15.92% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 13, 2026

Data Sources Report a data error